Table 4.

Associations between plasma NfL and clinical and laboratory variables in 72 SLE patients

	n (%)	β	95% CI	p-value
Renal involvement according to SLICC SLE Classification Criteria	29 (40%)	0.069	0.001–0.14	0.047
Anti-dsDNA positive according to SLICC SLE Classification Criteria	44 (61%)	0.077	0.009–0.15	0.027
P-Creatinine		0.003	0.001–0.006	0.009
S-Complement factor 3 < 0.8 g/L	44 (61%)	0.072	0.005–0.14	0.031
S-Complement factor 4 < 0.16 g/L	52 (72%)	−0.015	−0.092-0.061	0.69
SLICC/ACR-DI ≥1	25 (35%)	0.097	0.028–0.17	0.007
SLEDAI-2 K ≥1	45 (63%)	0.063	−0.006-0.13	0.075
SLEDAI-2 K ≥4	18 (25%)	0.023	−0.059-0.10	0.58
Ongoing treatment with glucocorticoids	57 (79%)	0.10	0.022–0.18	0.014
Ongoing treatment with non-antimalarial DMARDs	43 (60%)	0.091	0.025–0.16	0.008
Ongoing treatment with antihypertensives	22 (31%)	0.096	0.026–0.17	0.008

Linear regression models with plasma log-NfL concentrations as the dependent variable, all adjusted for age

NfL Neurofilament Light, n Number of subjects, β Unstandardized regression coefficient, 95% CI 95% confidence interval of β, SLICC Systemic Lupus International Collaborating Clinics, Anti-dsDNA Anti-double stranded DNA IgG antibodies, P Plasma, S Serum, ACR American College of Rheumatology, SLEDAI-2 K SLE Disease Activity Index 2000, DMARD Disease-modifying antirheumatic drug